An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate in Paediatric, Adolescent, and Adult Subjects With Von Willebrand Disease Who Completed Clinical Studies CSLCT-BIO-08-52 or CSLCTBIO-08-54
Latest Information Update: 05 Oct 2017
Price :
$35 *
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Sponsors CSL Behring
- 10 Nov 2014 New trial record